| 2026/03/13 | 16:44:17 | Urocross Expander System Officially Obtained U.S. FDA 510(k) Clearance | |
| SEQ_NO |
1 |
Date of announcement |
2026/03/13 |
Time of announcement |
16:44:17 |
| Subject |
Urocross Expander System Officially Obtained U.S. FDA 510(k) Clearance |
| Date of events |
2026/03/13
|
To which item it meets |
paragraph 10 |
| Statement |
1.Date of occurrence of the event:2026/03/13
2.New drug name or code:Urocross Expander System
3.Indication:
The Urocross Expander System is a retrievable, non-permanent implant
system developed to improve lower urinary tract symptoms (LUTS)
associated with Benign Prostatic Hyperplasia (BPH). The system gently
expands the prostatic urethral tissue through a minimally invasive
procedure performed under mild anesthesia, thereby relieving obstruction
and improving urinary flow.
4.Planned development stages:
The Urocross Expander System has officially obtained the 510(k) Clearance
from the U.S. FDA on 2026/03/13 (Taipei Time).
5.Current development stage:
(1) Submission of application / approval granted / approval not granted /
results of each phase of clinical trials (including interim analysis)
/ occurrence of other material events affecting new drug development:
The Urocross Expander System has officially obtained the U.S. FDA for
510(k) Clearance
(2) In the event that approval is not granted by the competent authority
for the intended use, or the results of any phase of clinical trials
(including interim analysis) fail to reach statistical significance,
or other material events occur that may affect new drug development,
the risks faced by the Company and corresponding countermeasures:
Not Applicable
(3) In the event that approval has been granted by the competent authority
for the intended use, or the results of any phase of clinical trials
(including interim analysis) reach statistical significance, or other
material events occur that may affect new drug development, the
Company’s future business plans and directions:
Not Applicable
(4) Cumulative research and development expenses incurred?G
Due to the involvement of information pertaining to future
international licensing negotiations, and to avoid impacting the deal
amount while safeguarding the rights and interests of investors, the
details will not be disclosed at this time.
6.Upcoming development plan:
Subsequent efforts will continue to advance preparations for product
launch while simultaneously conducting international strategic
collaboration discussions.
7.Market situation:
The probability of men suffering from BPH increases with age. The
estimated population in only the United States with BPH is reaching 40
million. As the population continues to age, the number of BPH patients
is expected to grow accordingly. According to a market research report by
Grand View Research, the global market for medical devices treating BPH
reached USD 1.67 billion in 2024. It is projected that from 2025 to 2033,
the BPH-related market will grow at a compound annual growth rate (CAGR)
of 9.4%, reaching USD 3.71 billion in 2033.
8.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 8
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):
The Company has successfully obtained 510(k) clearance, enabling it to
legally commence sales activities in the U.S. market. Commercialization
plans and mass production initiatives will be rolled out in phases.
Concurrently, the Company has initiated market entry plans for Taiwan,
including applying for Taiwanese regulatory approval and progressively
establishing sales channels. Market entry efforts will be dynamically
adjusted in alignment with global licensing negotiations and overall
strategic priorities, with the core objective of maximizing the project’s
overall value.
9.New drug development requires long process, vast investments and with
no guarantee in success which may pose investment risks.The investors
are advised to exercise caution and conduct thorough evaluation.: |
|
| 2026/03/02 | 17:48:10 | Medeon is invited to attend the investor conference held by MasterLink Securities | |
| SEQ_NO |
1 |
Date of announcement |
2026/03/02 |
Time of announcement |
17:48:10 |
| Subject |
Medeon is invited to attend the investor conference held by MasterLink Securities |
| Date of events |
2026/03/06
|
To which item it meets |
paragraph 12 |
| Statement |
1.Date of institutional investor conference:2026/03/06
2.Time of institutional investor conference:14:30
3.Location of institutional investor conference:
11F., No. 97, Sec. 2, Dunhua S. Rd., Taipei City (Tunnan Tower, 11F.,
Education and Training Room in MasterLink Securities)
4.Outline of institutional investor conference:
The Company is invited to attend the investor conference held by
MasterLink Securities to outline an overview of the Company’s current
operational status and future development plans.
5.Any other matters that need to be specified:None |
|
| 2026/02/26 | 18:18:17 | Medeon Board of Directors resolved the convening
of the 2026 Annual Shareholders’ Meeting | |
| SEQ_NO |
5 |
Date of announcement |
2026/02/26 |
Time of announcement |
18:18:17 |
| Subject |
Medeon Board of Directors resolved the convening
of the 2026 Annual Shareholders' Meeting |
| Date of events |
2026/02/26
|
To which item it meets |
paragraph 17 |
| Statement |
1.Date of the board of directors’ resolution?G2026/02/26
2.Shareholders meeting date?G2026/06/25
3.Shareholders meeting location?GConference Room, 11F, No. 97, Sec. 2, Dunhua S. Rd., Taipei City,
Taiwan (R.O.C.)
4.Shareholders’ meeting will be held by means of (physical shareholders’ meeting/ hybrid shareholders’ meeting / virtual-only shareholders’ meeting)?Gphysical shareholders’ meeting
5.Cause for convening the meeting (1)?GReport item(s)
(1)?GTo Report the Company’s 2025 Business Report
(2)?GTo Report Audit Committee’s Review Report on the
2025 Financial Statements
(3)?GTo Report the Implementation Status of the Private Placement
(4)?GTo Report the Directors’ Remuneration for the year 2025
(5)?GReport on the Implementation Status of the 2025 Cash Capital Increase Plan
for Strengthening Operations
6.Cause for convening the meeting (2)?GRatification Item(s)
(1)?GTo ratify the Company’s 2025 Business Report and Financial
(2)?GTo Ratify the Company’s 2025 deficit offset proposal
7.Cause for convening the meeting (3)?GDiscussion Item(s)
(1)?GProposal of the private placement by issuing common shares.
(2)?GTo approve the amendment to the Company’s Procedures for
Acquisition or Disposal of Assets.
(3)?GTo release directors or its representatives from
Non-Competition Restrictions
8.Extemporary Motions?G
9.Book closure starting date?G2026/04/27
10.Book closure ending date?G2026/06/25
11.Any other matters that need to be specified?G |
|
| 2026/02/26 | 17:45:45 | Medeon Board of Directors resolved the plan for dividend distribution | |
| SEQ_NO |
4 |
Date of announcement |
2026/02/26 |
Time of announcement |
17:45:45 |
| Subject |
Medeon Board of Directors resolved the plan for dividend distribution |
| Date of events |
2026/02/26
|
To which item it meets |
paragraph 14 |
| Statement |
1.Date of the board of directors resolution:2026/02/26
2.Year or quarter which dividends belong to :2025
3.Period which dividends belong to:2025/01/01~2025/12/31
4.Appropriations of earnings in cash dividends to shareholders (NT$
per share):0
5.Cash dividends distributed from legal reserve and capital reserve
to shareholders (NT$ per share):0
6.Total amount of cash dividends to shareholders (NT$):0
7.Appropriations of earnings in stock dividends to shareholders (NT$
per share):0
8.Stock dividends distributed from legal reserve and capital reserve
to shareholders (NT$ per share):0
9.Total amount of stock dividends to shareholders (shares):0
10.Any other matters that need to be specified:None
11.Per value of common stock:NT$10 |
|
| 2026/02/26 | 17:28:37 | Medeon Board of Directors resolved the proposal of private placement to issue additional common shares | |
| SEQ_NO |
2 |
Date of announcement |
2026/02/26 |
Time of announcement |
17:28:37 |
| Subject |
Medeon Board of Directors resolved the proposal of private placement to issue additional common shares |
| Date of events |
2026/02/26
|
To which item it meets |
paragraph 11 |
| Statement |
1.Date of the board of directors resolution:2026/02/26
2.Types of securities privately placed:The Company’s common shares
3.Counterparties for private placement and their relationship
with the Company:
According to Article 43-6 of the Securities and Exchange Act, the Financial
Supervisory Commission’s Order No. SFB 11220383220 issued on September 12,
2023, and the Directions for Public Companies Conducting Private Placement
of Securities, only the following parties are qualified as specific
investors of the private placement:
A.Insiders of the Company
The reason is that insiders know the operation of the Company very well
and can directly or indirectly contribute to the operation of the
Company. Therefore, placees in this instance of private placement include
the insiders. The list of these insiders is shown below:
a.The list of these insiders and the relation with the Company:
(1) Medeon, Inc. (USA)/ Institutional Director of the Company
(2) Center Laboratories, Inc./ Institutional Director of the Company
(3) Yue Teh Jang/ Representative of Medeon, Inc. of the USA, an
Institutional Director of the Company. Chairman and President of
the Company
(4) Jung-Chin Lin/ Representative of Center Laboratories, Inc.,
an Institutional Director of the Company
(5) Chih-Hsiung Wu/ Representative of Center Laboratories, Inc.,
an Institutional Director of the Company
(6) Chi-Hang Yang/ Independent Director of the Company
(7) Chia-Ying Ma/ Independent Director of the Company
(8) Jien-Wei Yeh/ Independent Director of the Company
(9) Feng Shyang Yang/ Independent Director of the Company
(10) Albert Weng/ Manager of the Company
(11) Greta Chang/ Manager of the Company
(12) Jenny Chen/ Manager of the Company
(13) Pei Chen/ Manager of the Company
(14) Javin Wang/ Accounting Officer of the Company
b.Institutional investors’ Names of the top 10 shareholders and
proportion of shareholding and the relation with the Company:
(1) Medeon, Inc. (USA)
Yue Teh Jang (100%)/ The Chairman of this company is the Chairman
and President of the Company.
(2) Center Laboratories, Inc.
Li Rong Technology Co., Ltd. (9.13%)/ The Chairman of this company
is the spouse of the representative of an Institutional Director of
the Company.
Royal Food Co., Ltd. (5.73%)/ The Chairman of this company is a
representative of an Institutional Director of the Company.
Jason Technology Co., Ltd. (3.51%)/ The Chairman of this company is
the spouse of the representative of an Institutional Director of
the Company.
Yuanta Securities Co., Ltd. in Custody for Mining Investment Fund
of GL Capital Group (2.71%)/ None
Farglory Life Insurance Inc. (1.48%)/ None
You De Investment Consulting Co., Ltd. (1.10%)/ The Chairman
of this company is also the Chairperson of an Institutional
Director of the Company.
Vanguard Total International Stock Index Fund, a series of Vanguard
Star Funds (1.04%)/ None
Mumozi Inc. (1.00%)/ None
Vanguard Emerging Markets Stock Index Fund, a Series of Vanguard
International Equity Index Funds (0.94%)/ None
Yong Lian Co., Ltd. (0.91%)/ None
B.Placees should be strategic investors: It is necessary to bring in
strategic investors that could contribute to the development of the
Company in the future, improvement of financial structure, and upgrade
the profitability of the Company. It is expected that with the assistance
of their capital, technology and knowledge, the Company will be able to
grow steadily in the future.
The Company has not yet pinpointed specific investors for investment. The
Company request the Shareholders’ Meeting to authorize the Board with full
power of attorney to search for the placees.
4.Number of shares or bonds privately placed:
Within the limit of 35,000,000 shares
5.Amount limit of the private placement:
Within the limit of 35,000,000 shares of common stock, the private
placement will be conducted in installments within one year from the date
of the shareholders’ meeting, with the maximum number of installments not
exceeding three.
6.Pricing basis of private placement and its reasonableness:
The reference price for the private placement is set at the higher of the
following two benchmark prices:
A.The average of the closing prices of common shares for one or three or
five (alternative) business days prior to the pricing date, excluding the
ex-rights and dividends of the nil-paid allotment of shares and after
adding back the capital reduction and ex-rights.
B.The average of the closing prices of the common shares for the 30
business days preceding the pricing date, excluding the ex-rights and
dividends of the nil-paid allotment, and after adding back the capital
reduction and ex-rights.
The price of common shares issued in the private placement shall be set at
a level not less than 80% of the reference price. The actual issuance price
of the private placement is proposed to the shareholders’ meeting to
authorize the board of directors to determine the price within a range not
lower than the percentage resolved at the shareholders’ meeting, taking
into account the prevailing market conditions on the pricing date.
7.Use of the funds raised in the private placement:
The purpose of each tranche is to increase working capital, accelerate
product development, invest in subsidiaries and the medical industry, and
develop the Group’s strategic objectives.
8.Reasons for conducting non-public offering:
Considering the timing, convenience and cost of issuance, private placement
of securities can be accomplished quickly and easily. In addition,
securities invested through private placement cannot be transferred in a
period of 3 years after issuing. This helps to assure the long-term stable
relation between the investors and the Company. As such, offering
securities through private placement is adopted.
9.Objections or qualified opinions from independent Board of Directors:None.
10.Actual price determination date:NA
11.Reference price:NA
12.Actual private placement price, and conversion or
subscription price:NA
13.Rights and obligations of these new shares privately placed:
In principle, the rights and obligations of the common shares in the
private placement are the same as those of the Company’s existing common
shares; however, in accordance with the Securities and Exchange Act, the
common shares in the private placement may not be sold within three years
from the date of delivery, except to the parties to whom they are
transferred in accordance with Article 43-8 of the Securities and Exchange
Act. After three years from the date of delivery, the Company intends to
request the shareholders’ meeting to authorize the Board of Directors to
apply to the relevant authorities for a public offering and listing of the
Company’s common shares in accordance with the relevant regulations.
14.Reference date for any additional share exchange, stock
swap, or subscription:NA
15.Possible dilution of equity in case of any additional share
exchange, stock swap, or subscription:NA
16.For additional share exchange or subscription, possible
influence of change in shareholding ratio of TPEx -listed
common shares if all privately placed corporate bonds are
converted and shares subscribed for (no.of TPEx -listed
common shares (a), (a) / outstanding common shares):NA
17.Please explain any countermeasures for lower circulation
in shareholding if the aforesaid estimated no.of TPEx -listed
common shares does not reach 5 million and the ratio does not
reach 25%:NA
18.Any other matters that need to be specified:
(1) The main contents of the private placement plan, including the actual
issue price, the number of shares to be issued, the terms of the issue,
the pricing date, the base date of the capital increase, the planned
projects, the amount to be raised, the estimated progress, the
estimated benefits to be generated, and all other matters related to
the issue plan, in addition to the pricing percentage of the private
placement. The above and in the future, in the event of changes in laws
and regulations, amendments as directed by the competent authorities,
or amendments based on operational evaluations or in response to
objective market conditions, the shareholders’ meeting will also be
requested to authorize the Board of Directors to handle such matters at
its sole discretion.
(2) In connection with the private placement of securities, it is proposed
that the shareholders’ meeting authorize the chairman of the board of
directors or his or her designee to sign and negotiate on behalf of the
Company all contracts and documents relating to the private placement
and to conduct all matters necessary for the Company in connection with
the private placement. |
|
| 2026/02/26 | 17:14:27 | Medeon Board of Directors approved the 2025 consolidated financial reports | |
| SEQ_NO |
1 |
Date of announcement |
2026/02/26 |
Time of announcement |
17:14:27 |
| Subject |
Medeon Board of Directors approved the 2025 consolidated financial reports |
| Date of events |
2026/02/26
|
To which item it meets |
paragraph 31 |
| Statement |
1.Date of the board of directors submitted or approved:2026/02/26
2.Date of the audit committee approved:2026/02/26
3.Start and end dates of financial reports or unaudited financial
information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):
2025/01/01~2025/12/31
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):419,425
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):58,825
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):(722,514)
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):(719,693)
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):(719,341)
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):(668,062)
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):(7.24)
11.Total assets end of the period (thousand NTD):1,779,793
12.Total liabilities end of the period
(thousand NTD):243,027
13.Equity attributable to owners of parent end of the
period (thousand NTD):1,475,740
14.Any other matters that need to be specified:None |
|
| 2026/02/25 | 16:09:37 | BOD of Medeon’s major subsidiary PMC resolved to convene the 2026 Annual Shareholders’ meeting | |
| SEQ_NO |
4 |
Date of announcement |
2026/02/25 |
Time of announcement |
16:09:37 |
| Subject |
BOD of Medeon’s major subsidiary PMC resolved to convene the 2026 Annual Shareholders’ meeting |
| Date of events |
2026/02/25
|
To which item it meets |
paragraph 17 |
| Statement |
1.Date of the board of directors resolution:2026/02/25
2.General shareholders’ meeting date:2026/05/29
3.General shareholders’ meeting location: Online Teams Meeting.
4.Cause for convening the meeting I.Reported matters:
(1) 2025 Business Report
(2) 2025 Supervisor’s Review Report
5.Cause for convening the meeting II.Acknowledged matters:
(1) 2025 Business Report and Financial Statements
(2) 2025 deficit offset proposal
6.Cause for convening the meeting III, Matters for Discussion:NA
7.Cause for convening the meeting IV.Election matters:NA
8.Cause for convening the meeting V.Other Proposals:NA
9.Cause for convening the meeting VI.Extemporary Motions:NA
10.Book closure starting date:2026/04/30
11.Book closure ending date:2026/05/29
12.Any other matters that need to be specified:NA |
|
| 2026/02/25 | 15:53:31 | BOD of Medeon’s major subsidiary PMC resolved not to distribute dividends | |
| SEQ_NO |
3 |
Date of announcement |
2026/02/25 |
Time of announcement |
15:53:31 |
| Subject |
BOD of Medeon’s major subsidiary PMC resolved not to distribute dividends |
| Date of events |
2026/02/25
|
To which item it meets |
paragraph 14 |
| Statement |
1.Date of the board of directors resolution:2026/02/25
2.Type and monetary amount of dividend distribution:not to distribute.
3.Any other matters that need to be specified:None. |
|
| 2026/02/25 | 15:45:15 | BOD of Medeon’s major subsidiary Medeologix Corporation resolved to convene the 2026 Annual Shareholders’ meeting | |
| SEQ_NO |
2 |
Date of announcement |
2026/02/25 |
Time of announcement |
15:45:15 |
| Subject |
BOD of Medeon’s major subsidiary Medeologix Corporation resolved to convene the 2026 Annual Shareholders’ meeting |
| Date of events |
2026/02/25
|
To which item it meets |
paragraph 17 |
| Statement |
1.Date of the board of directors resolution:2026/02/25
2.General shareholders’ meeting date:2026/05/29
3.General shareholders’ meeting location:Online Teams Meeting.
4.Cause for convening the meeting I.Reported matters:
(1) 2025 Business Report
(2) 2025 Supervisor’s Review Report
5.Cause for convening the meeting II.Acknowledged matters:
(1) 2025 Business Report and Financial Statements
(2) 2025 deficit offset proposal
6.Cause for convening the meeting III, Matters for Discussion:NA
7.Cause for convening the meeting IV.Election matters:NA
8.Cause for convening the meeting V.Other Proposals:NA
9.Cause for convening the meeting VI.Extemporary Motions:NA
10.Book closure starting date:2026/04/30
11.Book closure ending date:2026/05/29
12.Any other matters that need to be specified:NA |
|
| 2026/02/25 | 15:29:09 | BOD of Medeon’s major subsidiary Medeologix Corporation resolved not to distribute dividends | |
| SEQ_NO |
1 |
Date of announcement |
2026/02/25 |
Time of announcement |
15:29:09 |
| Subject |
BOD of Medeon’s major subsidiary Medeologix Corporation resolved not to distribute dividends |
| Date of events |
2026/02/25
|
To which item it meets |
paragraph 14 |
| Statement |
1.Date of the board of directors resolution:2026/02/25
2.Type and monetary amount of dividend distribution:not to distribute.
3.Any other matters that need to be specified:None. |
|
